Kidney Cancer Coalition, Inc., doing business as KidneyCAN, is a U.S. nonprofit organization headquartered in Philadelphia, Pennsylvania. Operating as a 501(c)(3) public charity, it focuses on accelerating cures for kidney cancer through patient advocacy, support for research funding, and facilitation of collaborations between researchers, government, and industry.
The organization provides direct financial support for clinical and laboratory studies and engages in efforts to advance kidney cancer research initiatives.
Also known as Kidney Cancer Coalition.
None yet. When a new project in the record names KidneyCAN as owner, partner or investor, it shows here.
FDA cleared PD‑1 plus HIF‑2α adjuvant regimens after Phase 3 showed 28% lower recurrence risk and 81% vs 74% 24‑month DFS; notable anemia, hypoxia and treatment discontinuations.
